Tandem Diabetes Care, Inc. (TNDM) SEC Filings & Earnings Calls

Continued net loss and operating loss despite improvement; GAAP net loss of $21.2M.

“GAAP net loss was $21.2 million, compared to GAAP net loss of $52.4 million in the second quarter 2025.”

Dependence on regulatory approvals for new products (Tandem Mobi tubeless capability 510(k) submission).

“Submitted 510(k) with the U.S. Food and Drug Administration (FDA) for Tandem Mobi tubeless capability.” · word for word

Infusion set supplier concentration

“one of our key infusion set suppliers has recently experienced supply challenges, which has impacted our overall inventory levels and supply sales, and we expect inventory constraints to persist through 2026.” · word for word

Pharmacy channel transition risk

“Under this model, in 2026, we began experiencing a decrease in sales and gross profit when pumps are shipped.” · word for word

Equity method investment risk

“Loss from equity method investment $(5,641) for Q2 2026.”

Convertible debt dilution risk

“17,262 shares reserved for issuance upon conversion of convertible senior notes as of June 30, 2026.”

Potential disruption in commercial operations.

“Mr. Novara’s last day of employment with the Company is scheduled to be May 18, 2026.”

International constant currency sales declined 5%, indicating FX headwinds and potential competitive pressure outside the US.

“International sales decreased 5% in constant currency.”

Operating loss persists despite improvement; GAAP operating loss -$17.4M, though significantly better than prior year.

“GAAP operating loss was $17.4 million, or negative 7% of sales.”

Pharmacy channel transition risk

“Under this model, in the first quarter of 2026, we began experiencing a decrease in sales and gross profit when pumps are shipped.” · word for word

International distributor destocking

“The decrease in pump shipments was attributable to distributor destocking in anticipation of our initiation of direct sales activities in select countries, which began in the first quarter of 2026.” · word for word

Reimbursement policy changes

“On December 2, 2025, the Centers for Medicare and Medicaid Services (CMS) finalized a proposed competitive bidding process for some medical equipment, including continuous glucose monitors and insulin pumps that could affect reimbursement rates for our products.” · word for word

Competitive pressure in diabetes technology market

“intensifying competition and global macroeconomic conditions.” · word for word

Dependence on pharmacy channel execution

“in 2026 we plan to drive utilization of the pharmacy benefits for all of our customers.” · word for word

GLP-1 drug adoption reducing insulin therapy market

“Since 2023, ongoing adoption of the GLP-1 class of drugs in diabetes and news surrounding the expansion of use of GLP-1 drugs in obesity has likely had a negative impact on the insulin therapy market.” · word for word

Pharmacy channel transition risk

“Under this new model, we may initially experience a decrease in sales and gross profit when pumps are shipped, and while we expect this decrease to be offset by an increase in supply sales and gross profit, there is no assurance that any decrease would be offset by these or other factors.” · word for word

Dependence on third-party suppliers and distributors

“We currently rely, and expect to continue to rely, on third-party suppliers to supply components of our current products and our potential future products, including our single-use insulin cartridges.” · word for word

Net loss of $204.7M for full year; operating loss of $187.3M.

“Net loss: GAAP net loss was $204.7 million... Operating loss: GAAP operating loss was $187.3 million.” · word for word

No material risk; standard board appointment.

Continued operating losses and negative adjusted EBITDA margin.

“GAAP operating loss of $22.9 million; Adjusted EBITDA margin of 1%.”

Guidance revision due to SEC staff views on IPR&D.

“Adjusted EBITDA margin guidance recast from ~3% to negative 5% due to IPR&D charge.”

Reimbursement Risk

“On June 30, 2025, CMS outlined a proposed competitive bidding process for some medical equipment, including continuous glucose monitors and insulin pumps that could affect reimbursement rates for our products.” · word for word

Product Recall Risk

“In March 2024, we issued a recall of our Apple iOS t:connect mobile app in the United States relating to an issue that could cause rapid depletion of a user’s t:slim X2 insulin pump battery.” · word for word

Cybersecurity Risk

“Cyberattacks aimed at our devices, products, services, or related systems, with the intent to alter or misuse them in ways that are inconsistent with our FDA clearances and approvals, could pose risks to users.” · word for word

Patent Litigation Risk

“Patent litigation in the medical device industry is common, and we may be subject to litigation that could cause us to incur substantial costs and divert the attention of management from our business.” · word for word

Regulatory Compliance Risk

“Our products and operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our business to suffer.” · word for word